Myriad Genetics, Inc.

NasdaqGS:MYGN Stock Report

Market Cap: US$1.3b

Myriad Genetics Past Earnings Performance

Past criteria checks 0/6

Myriad Genetics's earnings have been declining at an average annual rate of -15.6%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 2% per year.

Key information

-15.6%

Earnings growth rate

-11.8%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate2.0%
Return on equity-15.9%
Net Margin-14.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued

Jan 08
An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 13
Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Nov 02
Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Nov 02
Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

Sep 20
Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking

Aug 30
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking

Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?

Jul 17
Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

Jun 05
Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

May 11
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

May 09
Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Mar 28
Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Feb 02
An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Jan 31

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Dec 18
Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Aug 07
Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Apr 13
Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Revenue & Expenses Breakdown

How Myriad Genetics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:MYGN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24824-116563102
30 Jun 24802-15556098
31 Mar 24774-23556291
31 Dec 23753-26356789
30 Sep 23734-27458791
30 Jun 23699-24858188
31 Mar 23695-14655187
31 Dec 22678-11252785
30 Sep 22661-7744483
30 Jun 22672-1849481
31 Mar 22682-851380
31 Dec 21691-2753882
30 Sep 21684-5759980
30 Jun 21662-9754278
31 Mar 21566-14851476
31 Dec 20557-22450173
30 Sep 20598-19449974
30 Jun 20639-19950777
31 Mar 20761-14853981
31 Dec 19813-2654683
30 Sep 19835-1554786
30 Jun 19851555786
31 Mar 198302351283
31 Dec 187962647980
30 Sep 187675445174
30 Jun 1874413343571
31 Mar 1874913044472
31 Dec 1776312645971
30 Sep 1777110147273
30 Jun 177291744074
31 Mar 177573244675
31 Dec 167516341475
30 Sep 167489438573
30 Jun 1674111735971
31 Mar 1675712134970
31 Dec 1574710834969
30 Sep 157389535170
30 Jun 157238036676
31 Mar 157229535477
31 Dec 1472511035074
30 Sep 1474513733573
30 Jun 1477817632768
31 Mar 1476418731460

Quality Earnings: MYGN is currently unprofitable.

Growing Profit Margin: MYGN is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MYGN is unprofitable, and losses have increased over the past 5 years at a rate of 15.6% per year.

Accelerating Growth: Unable to compare MYGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).

Return on Equity

High ROE: MYGN has a negative Return on Equity (-15.85%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 23:16
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Myriad Genetics, Inc. is covered by 42 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack MeehanBarclays
Derek TallerBenchmark Company
Michael RyskinBofA Global Research